

| | |
|--|---------------------------------------|
| Referral Status: | MRN: |
| <input type="checkbox"/> New referral | <input type="checkbox"/> Order change |
| <input type="checkbox"/> Order Renewal | |
| Patient preferred clinic: | |

Stelara® (ustekinumab) Standard Plan of Treatment for Gastroenterology

PATIENT DEMOGRAPHICS:

| | |
|-----------------------------------|-------------------------------|
| Date of Referral: | Patient's Phone: |
| Patient Name: | Address: |
| Date of Birth: | City, State, Zip: |
| Height in inches: | Weight: LB or KG |
| Gender: | Allergies: |
| <input type="checkbox"/> See list | <input type="checkbox"/> NKDA |

DIAGNOSIS: (PLEASE COMPLETE 2ND AND 3RD DIGITS TO COMPLETE ICD 10 FOR BILLING)

| | |
|---|---|
| K50.0 - Crohn's disease (small intestine) | K51.2 - Ulcerative (chronic) proctitis |
| K50.1 - Crohn's disease (large intestine) | K51.3 - Ulcerative (chronic) rectosigmoiditis |
| K50.8 - Crohn's disease (small & large intestine) | K51.5 - Left sided colitis |
| K50.9 - Crohn's disease, unspecified | K51.8 - Other ulcerative colitis |
| K51.0 - Ulcerative (chronic) pancolitis | K51.9 - Ulcerative colitis, unspecified |
| - Other: | |

REQUESTED DOCUMENTATION:

PREVIOUS ADMINISTRATION: HAS THIS PATIENT TAKEN THIS MEDICATION BEFORE?

| | | | |
|---|--------------------------------|------------------|--|
| 1 | Insurance information | IF NO: | IF YES: |
| 2 | Most recent History & Physical | PLEASE STATE | LAST INFUSION DATE: |
| 3 | Full medication list | REQUIRED WASHOUT | NEXT INFUSION DATE: |
| 4 | Tried and failed therapies | FROM PREVIOUS | IF ORDER CHANGE: |
| 5 | TB screening | THERAPY: | |
| 6 | | | |
| | | | Continue current order until insurance approved |

MEDICATION ORDERS:

NOTE: Patient may be ineligible to receive ustekinumab if receiving antibiotics for active infectious process, antifungal therapy, active fever and/or suspected infection, new-onset or deterioration neurological changes, and/or surgery

PREMEDICATION TO BE ADMINISTERED 30 MINUTES PRIOR TO ADMINISTRATION AS SELECTED

FDA labeling does not suggest premedication.

| | | | | | | | | | | |
|-----------|--------------------|------|------------|--------|-----------|-----------------|-------|-------|-------|--------|
| IV | Diphenhydramine | 25mg | 50mg | Other: | PO | Acetaminophen | 325mg | 500mg | 650mg | 1000mg |
| | Methylprednisolone | 40mg | 125mg | | | Famotidine | 20mg | 40mg | | |
| | Famotidine | 20mg | 40 mg | | | Diphenhydramine | 25mg | 50mg | | |
| | | | | | | Fexofenadine | 60mg | 180mg | | |
| | | | | | | Cetirizine | 10mg | | | |
| | | | Loratadine | 10mg | | | | | | |
| | | | Other: | | | | | | | |

MEDICATION/DOSE/FREQUENCY:

Induction: Stelara® (ustekinumab) single IV dose per 250ml NS IV to infuse over at least 1 hour.

| Body weight of patient | Dose |
|------------------------|--------|
| less than 55 kg | 260 mg |
| 55-85 kg | 390 mg |
| greater than 85kg | 520 mg |

Maintenance: Stelara® (ustekinumab) 90 mg subcutaneously 8 weeks after initial IV and every 8

Administer as subcutaneous injection to upper arm, thigh, or abdomen.

Refills x 12 months unless noted otherwise here:

LINE USE/CARE ORDERS:

- Start PIV/Access CVC
- Flush device per facility standard flushing procedure

ADVERSE REACTION & ANAPHYLAXIS ORDERS:

Administer acute infusion and anaphylaxis medications per Palmetto Infusion standing adverse reaction orders, which can be found at our website or scan here.



PRESCRIBER INFORMATION:

| | |
|-------------------|--------|
| PROVIDER NAME: | PHONE: |
| ADDRESS: | FAX: |
| CITY, STATE, ZIP: | NPI: |

PRESCRIBER SIGNATURE: (No stamp signatures)

DATE:

| | |
|---|------------------------|
| | |
| Dispense as written/Brand medically necessary | Substitution permitted |